Glaxo, FDA, Vanderbilt to Study Genetic Basis of Long QT Side Effect | GenomeWeb

Glaxo, FDA, Vanderbilt to Study Genetic Basis of Long QT Side Effect

Dec 17, 2004

NEW YORK, Dec. 17 (GenomeWeb News) - The US Food and Drug Administration, GlaxoSmithKline, and Vanderbilt University will use First Genetic Trust's enTRUST genetic-banking and research technology to conduct a post-marketing study into the genetic basis for drug-induced Long QT.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

The Scan

Threats of Synthetic Biology

A new report highlights the potential threats posed by advances in synthetic biology, NPR reports.

Deletion Is Hard to Do

A Bloomberg reporter tried to get her genetic data deleted, but found it's not so simple to do.

So Just How Many Are There?

Johns Hopkins University's Steven Salzberg and his colleagues have come up with a new estimate for the number of human genes, Nature News reports.

This Week in Genome Research

In Genome Research this week: study of intra-tumor heterogeneity, workflow resources for EPIGEN-Brazil, and more.